Passions

Broadway musicals

My dog

Reality TV

Experience

Cooley Secures Dismissal of Derivative Action for FibroGen

October 9, 2024

Cooley successfully secured the complete dismissal of a derivative action for FibroGen – a biopharmaceutical company that discovers and develops medicines for the treatment of anemia, cancer and fibrotic disease – as well as certain officers and directors. The case is In re FibroGen Inc. Derivative Litigation, C.A. No. 2022-0331-SG (Del. Ch.).

Read more

Related contacts

Patrick Gibbs
Partner, Palo Alto
Tijana Brien
Partner, Palo Alto
Brett De Jarnette
Partner, Palo Alto
Amie Simmons
Associate, Palo Alto
Kimberley Scimeca
Associate, Boston
Madeleine McNally
Associate, Palo Alto

Related Practices & Industries

Dutch Bros Secures Motion to Dismiss in Securities Class Action

June 24, 2024

Cooley successfully secured a ruling dismissing a securities class action against Dutch Bros and two of its former senior executives in its entirety and with prejudice, a rare result on a first-round motion to dismiss. The case is Douglas Rein v. Dutch Bros. Inc. et al. before the US District Court for the Southern District of New York.

Read more

Related contacts

Patrick Gibbs
Partner, Palo Alto
Caitlin B. Munley
Associate, Washington, DC
Kimberley Scimeca
Associate, Boston

Related Practices & Industries

Cooley Secures Win for FibroGen in Securities Fraud Class Action

March 15, 2024

Cooley successfully narrowed the class period, thereby substantially reducing the plaintiffs’ potential damages, in a securities class action against client FibroGen – a biopharmaceutical company that discovers and develops medicines for the treatment of anemia, cancer and fibrotic disease.

Read more

Related contacts

Patrick Gibbs
Partner, Palo Alto
Tijana Brien
Partner, Palo Alto
Brett De Jarnette
Partner, Palo Alto
Alexandra Eber
Special Counsel, Washington, DC
Caitlin B. Munley
Associate, Washington, DC
Amie Simmons
Associate, Palo Alto
Kimberley Scimeca
Associate, Boston

Related Practices & Industries

Biotech Company ViaCyte to Be Acquired by Vertex Pharmaceuticals

July 14, 2022

Cooley advised ViaCyte, a biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for Type 1 diabetes (T1D), on its definitive agreement to be acquired by global biotechnology company Vertex Pharmaceuticals for $320 million in cash. Partners Rowook Park and Carlos Ramirez, along with associate Lindsey O’Crump, led the Cooley team advising ViaCyte.

Read more

Related contacts

Rowook Park
Partner, San Diego
Carlos Ramirez
Partner, San Diego
Rama Padmanabhan
Partner, San Diego
Marty Schenker
Senior Counsel , San Francisco
Todd Gluth
Partner, San Diego
Blake Martell
Of counsel, San Francisco
Charity Williams
Partner, San Diego
Jeffrey Karr
Of Counsel, Palo Alto
Ross Eberly
Partner, Santa Monica
Phil Mitchell
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC
Dina Andrawess
Special Counsel, Palo Alto
Stella Sarma
Partner, Brussels
Lindsey O'Crump
Associate, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Kimberley Scimeca
Associate, Boston

Related Practices & Industries

Admissions and credentials

Massachusetts

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.